Nimbus Receives Additional Funding to Further Develop Protein Targets for Drug Development

The funds will be used to advance the company's lead programs in diffuse large B-cell lymphoma, inflammatory disorders, and metabolic disease.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories